Parameter | Value (range) | Source |
---|---|---|
Age, yr, mean | 35.9 | Patient data from MRHC |
Age at symptom onset, yr | 55 (36–84) | Whitty et al.21 |
Probability | ||
Of patient being female | 0.487 | Patient data from MRHC |
Of patient being infected | 0.232 (0.181–0.293) | Patient data from MRHC |
Of test result being positive, given presence of infection | 0.99 | NRCP22 |
Of test result being negative, given absence of infection | 0.90 | NRCP22 |
Of patient consenting to screening test | 0.98 | Patient data from MRHC |
Of patient accepting treatment, given positive test result | 0.88 (0.82–0.94) | Patient data from MRHC |
Of patient accepting empiric treatment | 0.88 (0.82–0.94) | Patient data from MRHC |
Of patient being cured by treatment | 0.88 (0.799–0.929) | Whitty et al.,21 Danso-Appiah et al.23 |
Of hepatosplenic (v. urinary) involvement, given infection | 0.45 | Patient data from MRHC |
Of urinary obstruction, given infection | 0.287 (0–0.431) | Smith et al.24 |
Of hydronephrosis, given infection | 0.228 (0–0.342) | Smith et al.24 |
Of pyelonephritis, given obstruction | 0.197 (0–0.295) | Smith et al.24 |
Of bacteremia, given pyelonephritis | 0.143 (0–0.341) | Stamm25 |
Of genital disease, given infection in female | 0.333 (0–0.500) | Gelfand et al.26 |
Of bladder cancer, given infection | 0.027 (0–0.041) | Smith et al.24 |
Of intestinal disease, given infection | 0.133 (0–0.200) | Prata27 |
Of portal fibrosis, given infection | 0.139 (0–0.209) | Cheever and Andrade28 |
Of ascites, given fibrosis | 0.070 (0.010–0.100) | Andrade29 |
Of hematemesis, given fibrosis | 0.027 (0–0.040) | Saad et al.30 |
Of death, given hematemesis | 0.153 (0–0.230) | Reboucas31 |
Of pulmonary hypertension, given fibrosis | 0.186 (0–0.230) | Prata27 |
Of cor pulmonale, given fibrosis | 0.050 (0–0.075) | Prata27 |
Of glomerulonephritis, given fibrosis | 0.067 (0–0.100) | Prata27 |
Of central nervous system involvement, given infection | 0.001 (0–0.002) | Cheever and Andrade28 |
Standardized mortality ratio for refugees in Canada | 0.53 | DesMeules et al.32 |
Mean life expectancy at age 36 yr for Canadians, yr | 46.7 | Statistics Canada33 |
Mean life expectancy at age 36 yr for refugees resettled in Canada, yr | 52.9 | DesMeules et al.,32 Statistics Canada33 |
Mean survival for patients with glomerulonephritis, yr | 17.3 | Heaf et al.34 |
Mean survival for patients with pulmonary hypertension, yr | 9.4 | Oswald-Mammosser et al.35 |
Mean survival for patients with bladder cancer, yr | 5.3 | Ehdaie et al.36 |
Mean survival for patients with cor pulmonale, yr | 7.0 | Opitz et al.37 |
Mean survival for patients with portal hypertension, yr | 27.8 | Siramolpiwat et al.38 |
Duration of treatment for infertility, yr | 4.1 | Collins et al.39 |
Utility discount rate, % | 1.5 | CADTH40 |
Cost discount rate, % | 1.5 | CADTH40 |
Mean dose of praziquantel, mg | 1000 | Personal communications* |
Cost of praziquantel, $ | 47.93 (44.66–51.19) | Personal communications* |
Cost of serology, $ | 74.09 (61.21–86.97) | Personal communications† |
Note: CADTH = Canadian Agency for Drugs and Technology in Health, MRHC = Mosaic Refugee Health Clinic, NRCP = National Reference Centre for Parasitology.
↵* Personal communications: David Brewerton, pharmacist, Luke’s Drug Mart, Calgary; Joel Varsava, pharmacist, Pharmacity, Ottawa (for additional detail, see Appendix 1, available at www.cmajopen.ca/content/9/1/E125/suppl/DC1).
↵† Personal communications: Jayne Jones, Liverpool School of Tropical Medicine, and Mary Kamb, department of public inquiries, Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention (for additional detail, see Appendix 1).